文献速递胸部肿瘤支持与姑息治疗

36例PS评分2-4分晚期非小细胞肺癌患者的临床分析

[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

回顾性分析36例以低氧血症为主要表现的晚期NSCLC(PS评分2-4分)患者,给予支持治疗PS评分从3.4±0.5降至2.5±0.7,SPO2从89.0±5.2%升至95.0±3.5%;一线抗肿瘤治疗后临床获益率66.7%,疾病控制率77.8%,PFS为10.0±6.5个月。结论强调在控制原发肿瘤同时积极治疗并发症,改善PS评分以争取抗肿瘤机会,并重视二次活检。

要点

  • PS≥2分晚期NSCLC应积极支持治疗改善PS,为抗肿瘤创造条件。
  • 本研究临床获益率66.7%、疾病控制率77.8%,PFS 10.0±6.5个月。
  • 疾病进展后应重视二次活检和基因检测,检测率63.6%。

核心结论

  • 对于PS≥2分的晚期NSCLC患者,应在控制原发肿瘤的同时积极治疗并发症,在最短时间内选择最佳治疗方案以改善PS评分,为抗肿瘤治疗提供机会。
  • 同时要重视肿瘤的异质性和二次活检。

研究设计与样本

  • 回顾性分析36例以低氧血症为主要表现的晚期NSCLC(PS评分2-4分)患者的临床资料。
  • 收集疾病特征、低氧血症原因、并发症、呼吸支持、抗肿瘤治疗方案、肿瘤进展和二次活检情况。
  • 疗效依据RECIST分为CR、PR、SD和PD。

主要发现

  • 36例患者均有低氧血症,31例(86.1%)合并其他基础疾病,20例(55.6%)应用无创呼吸机辅助呼吸支持。
  • 28例(77.8%)应用广谱抗生素治疗,其中22例(78.6%)抗感染治疗后肺部渗出影减轻。
  • 15例行床边纤维支气管镜吸痰,其中2例因大气道阻塞置放气道支架;4例行胸腔引流术;4例行抗凝治疗;1例经溶栓处理。
  • 非肿瘤治疗前后PS评分分别为(3.4±0.5)分和(2.5±0.7)分,SPO2分别为(89.0±5.2)%和(95.0±3.5)%。
  • 首次评估CR 1例、PR 23例、SD 4例、PD 8例,临床获益率66.7%,疾病控制率77.8%;22例出现PD,其中8例行二次活检、6例行二代测序,检测率63.6%;生存10例(27.8%),PFS为(10.0±6.5)个月。

关键数值与推荐

  • 疗效评价采用RECIST标准,分为CR、PR、SD和PD。
  • 一线抗肿瘤治疗:口服靶向药9例;培美曲塞+贝伐单抗或卡铂方案13例;紫杉醇+卡铂方案8例;吉西他滨+卡铂方案4例;多西他赛+吉西他滨方案2例。
  • 临床获益率为66.7%,疾病控制率为77.8%,二次活检率为63.6%(8/22例PD患者中行二次活检)。

临床怎么用

  • 对PS≥2分晚期NSCLC患者,应先积极处理低氧血症、感染等并发症并给予呼吸支持,以改善PS评分。
  • 在PS改善后应尽快选择合适的一线抗肿瘤方案(靶向、含铂化疗或联合抗血管生成等)。
  • 疾病进展后应重视二次活检和基因检测,以指导后续治疗。

局限性

  • 本研究为单中心回顾性分析,样本量仅36例。
  • 未设对照组,结论的推广需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the treatment of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4, in order to improve the diagnosis and treatment of these patients. Methods: A total of 36 patients with advanced NSCLC with hypoxemia were reviewed. The clinical data of disease characteristics, etiology, complications, manifestation, therapy, progression, and secondary biopsy were collected. The clinical efficacy was graded according to the Response Evaluation Criteria In Solid Tumors (RECIST): complete response (CR), partial response (PR), stable disease (SD) and disease progression (PD). Results: All patients had hypoxemia, of whom 86.1% (31 patients) had complications and 55.6% (20 patients) had noninvasive ventilator for respiratory support. 77.8% (28 cases) received broad-spectrum antibiotic treatment, and 78.6% of them got lung osmotic relief after the anti-infection treatment. 15 cases received bedside fiberoptic bronchoscopy suction, of whom two cases were treated with airway stent deposition due to airway obstruction, four cases with thoracic drainage, four cases with anticoagulation, and one with thrombolytic therapy. After these supportive treatment, the PS score of these patients decreased from 3.4±0.5 to 2.5±0.7, while SPO(2) improved from (89.0±5.2)% to (95.0±3.5)%. As first-ling anti-cancer treatment, nine patients were administrated with targeted medicine orally, 13 patients with a combined chemotherapy of pemetrexed plus bevacizumab or carboplatin, eight patients with paclitaxel plus carboplatin, four patients with gemcitabine plus carboplatin, and two patients with docetaxel plus gemcitabine. In the first response evaluation, there were one case of CR, 23 cases of PR, four cases of SD, and eight cases of PD, with a clinical benefit rate of 66.7% and a disease control rate of 77.8%. A total of 22 patients experienced disease progression, of whom eight cases had a secondary biopsy and six cases had gene sequencing. Of these 36 patients, 10 (27.8%) patients survived at the last follow-up, with a progression-free survival of (10.0±6.5) months. Conclusion: Besides prompt anti-cancer treatment and best supportive treatment should be incorporated to improve PS and improve outcome. 目的: 分析体力状况(PS)评分≥2分的晚期非小细胞肺癌(NSCLC)患者的临床特点,提高其诊治水平。 方法: 回顾性分析36例以低氧血症为主要表现的晚期NSCLC患者的临床特点、低氧血症的原因、并发症、呼吸支持情况、抗肿瘤治疗方案、肿瘤进展和二次活检情况。疗效依据实体瘤的疗效评价标准分为完全缓解(CR)、部分缓解(PR)、稳定(SD)和进展(PD)。 结果: 36例晚期NSCLC患者均有低氧血症,其中31例(86.1%)患者合并其他基础疾病,20例(55.6%)患者应用无创呼吸机辅助呼吸支持。有28例(77.8%)患者应用广谱抗生素治疗,其中22例(78.6%)患者在抗感染治疗后肺部渗出影减轻。有15例患者行床边纤维支气管镜吸痰,其中2例因大气道阻塞而置放气道支架,4例行胸腔引流术,4例行抗凝治疗,1例经溶栓处理。在非肿瘤治疗前后,36例晚期NSCLC患者的PS评分分别为(3.4±0.5)分和(2.5±0.7)分,脉搏血氧饱和度(SPO(2))分别为(89.0±5.2)%和(95.0±3.5)%。在一线抗肿瘤治疗中,口服靶向药9例,采用含培美曲塞+贝伐单抗或卡铂方案13例,采用紫杉醇+卡铂方案8例,采用吉西他滨+卡铂方案4例,采用多西他赛+吉西他滨方案2例。首次评估时,CR 1例,PR 23例,SD 4例,PD 8例,临床获益率为66.7%,疾病控制率为77.8%。在治疗期间,有22例患者出现PD,其中行二次活检8例,二代测序6例,检测率为63.6%。36例晚期NSCLC患者中,生存10例(27.8%),无进展生存时间(PFS)为(10.0±6.5)个月。 结论: 对于PS≥2分的NSCLC患者,应在控制原发肿瘤的同时,积极治疗并发症,并在最短时间内选择最佳的治疗方案,控制病情,改善PS评分,为抗肿瘤治疗提供机会。同时要重视肿瘤的异质性和二次活检。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qin YY, Zhang DH, Lin XQ, et al. [Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 29151293. doi:10.3760/cma.j.issn.0253-3766.2017.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。